Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
REGENERON PHARMACEUTICALS INC	777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591-6707

International Classification(s)

• C07K:PEPTIDES

• 2015 Application Filing Year
• C07K Class
• 5128 Applications Filed
• 3629 Patents Issued To-Date
• 70.77 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Bessac, Laurence	Paris, FR	22	280
# of filed Patents : 22 Total Citations : 280
Chaudhari, Umesh	Bridgewater, US	16	156
# of filed Patents : 16 Total Citations : 156
Hanotin, Corinne	Paris, FR	26	301
# of filed Patents : 26 Total Citations : 301
Pordy, Robert	Tarrytown, US	2	13
# of filed Patents : 2 Total Citations : 13
Schwemmer, Gipe Daniel A	Tarrytown, US	9	58
# of filed Patents : 9 Total Citations : 58

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 9 Citation Count
• C07K Class

• 52.71 % this patent is cited more than
• 9 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Nov 19, 2027

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2016/0137,746

METHODS FOR TREATING HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA

---

Abstract

---

The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.